For Asia-manufactured exosome / extracellular vesicle programs, Esco Aster, CoJourney Inc., and Exopharm lead CDMO Signal's ranking of exosome / extracellular vesicle CDMOs with confirmed Asian manufacturing sites. Filtered from the global directory of 7 scored exosome / extracellular vesicle CDMOs to 4 with Asia-Pacific facility presence. Asian CDMOs cover a range of regulatory jurisdictions — PMDA (Japan), NMPA (China), MFDS (South Korea), CDSCO (India) — each with distinct requirements. For sponsors supplying US and EU markets, cross-jurisdictional regulatory posture (FDA and EMA/MHRA inspection history on Asian facilities) is typically the qualifying signal. Rankings update as new inspection and certificate data enters the platform. Full methodology at cdmosignal.com/methodology.
Exosome and extracellular vesicle (EV) CDMOs manufacture next-generation delivery vehicles for RNA, proteins, and small molecules. As an emerging modality, the field is still standardizing cell-source, isolation, and potency methods.
Choosing an exosome CDMO turns on cell-source and culture scale, isolation method (TFF, chromatography), characterization, and a clean regulatory record. The rankings below score each CDMO on FDA inspections, GMP certification, clinical activity, and capacity.
Last updated 2026-08-01. Sourced from FDA, EMA EudraGMDP, MHRA GMDP, and ClinicalTrials.gov.
#
CDMO
Signal Score
Quality
FDA · GMP
Capacity
Programs
1
EA
Esco Aster
Singapore, SG
63.0
—
—
—
0 programs
2
CoJourney Inc.
Horsham, PA (US HQ); Hangzhou, China (primary GMP manufacturing)
What to evaluate in a Exosome / Extracellular Vesicle CDMO
Cell source & scale
Confirm the producer cell source and whether culture is suspension-adapted for the volumes EV yields demand.
Isolation & purification
Isolation method (tangential-flow filtration, chromatography) drives yield, purity, and scalability. Ask how it performs at your target scale.
Characterization & potency
EV characterization (particle count, size, cargo, identity) and potency assays are still maturing — look for established, qualified methods.
Regulatory track record
Cross-check FDA 483 history and EMA/MHRA GMP coverage — both shown above and on each profile.
Regulatory landscape across PMDA (Japan), NMPA (China), MFDS (South Korea)
Asian biopharma manufacturing spans multiple national regulators. PMDA (Japan) is generally regarded as one of the most stringent in Asia, with GMP requirements broadly aligned with FDA and EMA. NMPA (China) has substantially strengthened its GMP framework over the past decade, and Chinese CDMOs increasingly hold FDA and EMA certifications alongside NMPA registration. MFDS (South Korea) certification is standard for Korean CDMOs. For sponsors supplying US or EU markets, the qualifying signal for an Asian CDMO is typically FDA and EMA inspection history on the specific facility — which the Signal Score's Quality Compliance pillar captures directly.
Which Asian CDMOs cover FDA (US) and EMA/MHRA (Europe) regulatory geographies?
Asian CDMOs with US FDA and European EMA/MHRA inspection history are qualified to supply global markets; those without cross-jurisdictional inspection posture are typically limited to their home-market regulatory scope. The Signal Score's Quality Compliance pillar includes FDA + EMA + MHRA data directly, so Asian CDMOs with cross-jurisdictional certification typically rank higher on this pillar than home-market-only competitors. Sponsors evaluating an Asian CDMO for a US or EU program should cross-check with the US region ranking and Europe region ranking — CDMOs appearing across regions have demonstrated multi-jurisdictional posture.
Recent US regulatory events affecting Asian CDMO selection (WuXi 1260H, BioSecure Act considerations)
Asian CDMOs — particularly Chinese-headquartered players — are subject to US regulatory events that affect sponsor risk assessment. The US Department of Defense's 1260H list (which added WuXi AppTec in June 2026) and the BioSecure Act (proposed federal legislation restricting federally-funded research and Medicare/Medicaid drug programs from working with named Chinese biotech companies) are both active considerations. CDMO Signal's platform does not encode US political risk into the Signal Score directly — the composite reflects regulatory quality, operations, financial stability, and capacity signals. Sponsors weighing an Asian CDMO for a US-supplying program should evaluate US regulatory risk separately as a distinct decision layer alongside the Signal Score-based capability assessment.
Who are the top Exosome / Extracellular Vesicle CDMOs?
By CDMO Signal's independent Signal Score, the top-ranked Exosome / Extracellular Vesicle CDMOs include Esco Aster, CoJourney Inc., Exopharm. See the full ranked table above — scored on FDA, clinical, financial, and capacity data.
What should I look for in an exosome CDMO?
Confirm cell source and scalable culture, a robust isolation method (TFF or chromatography), qualified characterization and potency analytics, and a clean FDA and EMA/MHRA record.
Is exosome manufacturing standardized?
Not yet fully — cell-source, isolation, and potency methods are still maturing across the field, so a CDMO's specific platform and analytics maturity matter more than in established modalities.